At DCAT Week we sat down with Dennis Angioletti, Group Head of Commercial and Business Development at HAS Group, to discuss the company’s 2025 acquisition of Cerbios and the strategic vision behind it.
TWENTYFOURSEVENBIOPHARMA
At DCAT Week we sat down with Dennis Angioletti, Group Head of Commercial and Business Development at HAS Group, to discuss the company’s 2025 acquisition of Cerbios and the strategic vision behind it.